MX2010004982A - Metodos y composiciones para medir la activacion de wnt y para el tratamiento de canceres relacionados con wnt. - Google Patents

Metodos y composiciones para medir la activacion de wnt y para el tratamiento de canceres relacionados con wnt.

Info

Publication number
MX2010004982A
MX2010004982A MX2010004982A MX2010004982A MX2010004982A MX 2010004982 A MX2010004982 A MX 2010004982A MX 2010004982 A MX2010004982 A MX 2010004982A MX 2010004982 A MX2010004982 A MX 2010004982A MX 2010004982 A MX2010004982 A MX 2010004982A
Authority
MX
Mexico
Prior art keywords
wnt
methods
compositions
measuring
treating
Prior art date
Application number
MX2010004982A
Other languages
English (en)
Inventor
Feng Cong
Atwood Cheung
Shih-Min Huang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2010004982A publication Critical patent/MX2010004982A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente solicitud describe métodos para regular o modular (por ejemplo, antagonizar o inhibir) la señalización de Wnt, mediante la administración de estabilizantes de Axina. La solicitud también describe método para utilizar los estabilizantes de Axina descritos en la presente para el tratamiento, el diagnóstico, la prevención, y/o la mitigación de los trastornos relacionados con la señalización de Wnt.
MX2010004982A 2007-11-05 2008-11-05 Metodos y composiciones para medir la activacion de wnt y para el tratamiento de canceres relacionados con wnt. MX2010004982A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98545407P 2007-11-05 2007-11-05
PCT/EP2008/064987 WO2009059994A2 (en) 2007-11-05 2008-11-05 Methods and compositions for measuring wnt activation and for treating wnt-related cancers

Publications (1)

Publication Number Publication Date
MX2010004982A true MX2010004982A (es) 2010-08-16

Family

ID=40626253

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004982A MX2010004982A (es) 2007-11-05 2008-11-05 Metodos y composiciones para medir la activacion de wnt y para el tratamiento de canceres relacionados con wnt.

Country Status (11)

Country Link
US (1) US20100267626A1 (es)
EP (1) EP2217223A2 (es)
JP (1) JP2011504461A (es)
KR (1) KR20100089869A (es)
CN (1) CN101854924A (es)
AU (1) AU2008324203A1 (es)
BR (1) BRPI0820504A2 (es)
CA (1) CA2704648A1 (es)
EA (1) EA201000673A1 (es)
MX (1) MX2010004982A (es)
WO (1) WO2009059994A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
US9874553B2 (en) * 2008-09-10 2018-01-23 New York University Targeted chemical high-throughput screening method
NZ592338A (en) 2008-09-26 2012-11-30 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
US8268550B2 (en) 2009-06-26 2012-09-18 Massachusetts Institute Of Technology Compositions and methods for identification of PARP function, inhibitors, and activators
US20110097329A1 (en) 2009-06-26 2011-04-28 Massachusetts Institute Of Technology Compositions and methods for treating cancer and modulating stress granule formation
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
DK3311666T3 (da) 2010-08-18 2021-06-28 Biosplice Therapeutics Inc Diketoner og hydroxyketoner som aktivatorer af catenin-signalvejen
HUE039849T2 (hu) 2011-03-16 2019-02-28 Argenx Bvba CD70 elleni ellenanyagok
US9181266B2 (en) 2011-07-13 2015-11-10 Novartis Ag 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
US9163003B2 (en) 2011-07-13 2015-10-20 Novartis Ag 4-piperidinyl compounds for use as tankyrase inhibitors
EP2731951B1 (en) 2011-07-13 2015-08-19 Novartis AG 4-oxo-3,5,7,8-tetrahydro-4h-pyrano {4,3-d} pyrminidinyl compounds for use as tankyrase inhibitors
KR101376338B1 (ko) * 2011-09-06 2014-03-19 재단법인 제이씨비 공동생물과학연구소 스타틴계 약물 및 윈트 신호 전달 조절제를 유효성분으로 함유하는 동맥경화증 및 뇌졸중의 예방 또는 치료용 약학 조성물
US20150132301A1 (en) * 2011-12-09 2015-05-14 Oncomed Pharmaceuticals, Inc. Combination Therapy for Treatment of Cancer
CN104302768A (zh) * 2012-01-09 2015-01-21 诺华股份有限公司 治疗β-联蛋白相关疾病的有机组合物
RU2696572C2 (ru) 2012-03-07 2019-08-05 Инститьют Оф Кансер Ресёрч: Ройял Кансер Хоспитал (Зе) 3-арил-5-замещенные соединения изохинолин-1-она и их терапевтическое применение
AU2013368945B2 (en) 2012-12-26 2020-01-23 Innosign B.V. Assessment of cellular signaling pathway activity using linear combination(s) of target gene expressions
US9359444B2 (en) 2013-02-04 2016-06-07 Oncomed Pharmaceuticals Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
EP2968249B1 (en) 2013-02-22 2018-11-14 Samumed, LLC Gamma-diketones as wnt/beta -catenin signaling pathway activators
DK3044221T3 (en) 2013-09-11 2018-04-23 Institute Of Cancer Res Royal Cancer Hospital The 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ON COMPOUNDS AND THERAPEUTIC APPLICATION THEREOF
UY36060A (es) 2014-04-02 2015-10-30 Bayer Pharma AG Compuestos de azol sustituidos con amida
KR102165385B1 (ko) 2014-08-20 2020-10-15 사뮤메드, 엘엘씨 피부 노화 및 주름의 치료 및 예방을 위한 감마-디케톤
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
WO2017055313A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
WO2017055316A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
WO2018078009A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives
WO2018078005A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted azaspiro derivatives as tankyrase inhibitors
WO2018087126A1 (en) 2016-11-09 2018-05-17 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives as inhibitors of tankyrase
CN106619622A (zh) * 2016-12-14 2017-05-10 中国科学院昆明植物研究所 以丙酰胺类化合物为活性成分的药物组合物和其在制药中的应用
EP3691649B1 (en) 2017-10-06 2022-10-12 Eluciderm Inc. Compositions and methods for wound treatment
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
TW202038958A (zh) 2018-12-18 2020-11-01 比利時商阿根思公司 Ｃｄ７０組合治療
US20230277540A1 (en) 2020-06-09 2023-09-07 Genethon Treatment of Dilated Cardiomyopathies
KR20220139674A (ko) 2021-04-08 2022-10-17 동아대학교 산학협력단 PFKP를 포함하는 Wnt 신호 전달로 발달된 종양 진단용 바이오마커 및 이의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635642B1 (en) * 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US20120178697A9 (en) * 2003-09-22 2012-07-12 Jie Zheng Compositions and methods for the inhibition of dishevelled proteins
DK2305221T3 (en) * 2003-12-01 2015-08-24 Kudos Pharm Ltd DNA damage repair inhibitors for the treatment of cancer
US20060035939A1 (en) * 2004-07-14 2006-02-16 Japan Tobacco Inc. 3-Aminobenzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity
WO2006055635A2 (en) * 2004-11-15 2006-05-26 Mount Sinai School Of Medicine Of New York University Compositions and methods for altering wnt autocrine signaling
EP1858922A2 (en) * 2005-03-18 2007-11-28 The Genetics Company, Inc. A novel component of the wg/wnt signaling pathway

Also Published As

Publication number Publication date
WO2009059994A2 (en) 2009-05-14
BRPI0820504A2 (pt) 2015-06-16
JP2011504461A (ja) 2011-02-10
EP2217223A2 (en) 2010-08-18
EA201000673A1 (ru) 2011-04-29
US20100267626A1 (en) 2010-10-21
CA2704648A1 (en) 2009-05-14
CN101854924A (zh) 2010-10-06
KR20100089869A (ko) 2010-08-12
WO2009059994A3 (en) 2009-12-10
AU2008324203A1 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
MX2010004982A (es) Metodos y composiciones para medir la activacion de wnt y para el tratamiento de canceres relacionados con wnt.
TW200801021A (en) Imidazolothiazole compounds for the treatment of disease
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
WO2011146879A3 (en) Methods and compositions related to modulating autophagy
TN2009000323A1 (en) Modulators of sclerostin binding partners for treating bone-related disorders
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
WO2010021693A3 (en) Mif modulators
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
MY189750A (en) Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
GEP20146082B (en) Compositions and methods of wnt signaling modulators
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
MY165728A (en) Selective glycosidase inhibitors and uses thereof
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
MY173795A (en) Novel benzopyran kinase modulators
WO2011140202A3 (en) Mif modulators
UA113397C2 (xx) Попередження несприятливих ефектів, спричинених специфічними доменами зв'язування cd3
EA201291107A1 (ru) Соединения, ингибирующие металлоферменты
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
TW200806325A (en) Therapeutic uses of inhibitors of RTP801
MY148780A (en) Tricyclic compounds, compositions, and methods
WO2011141823A3 (en) Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX2009013676A (es) Metodos y composiciones para inhibir el factor de edema y la adenilil ciclasa.
UA99936C2 (en) Biaryl substituted azabicyclic alkane derivatives

Legal Events

Date Code Title Description
FA Abandonment or withdrawal